HOPE4Cancer

  • Research type

    Research Study

  • Full title

    Hypothermic oxygenated perfusion (HOPE) against cancer recurrence in HCC liver transplantation - International multicentre parallel group interventional RCT

  • IRAS ID

    354376

  • Contact name

    Miriam Cortes Cerisuelo

  • Contact email

    m.cortescerisuelo@nhs.net

  • Sponsor organisation

    University Digestive Health Care Centre Basel

  • Clinicaltrials.gov Identifier

    NCT06717919

  • Duration of Study in the UK

    3 years, 7 months, 31 days

  • Research summary

    Liver transplantation is a life-saving procedure for patients with hepatocellular carcinoma (HCC), a type of liver cancer. However, some patients experience cancer recurrence after the transplant. The HOPE4Cancer study aims to investigate whether a technique called hypothermic oxygenated perfusion (HOPE/DHOPE) can reduce the risk of HCC returning after a liver transplant.
    HOPE/DHOPE is a method where a donated liver is treated with oxygenated cold fluid before transplantation. This technique has been shown to improve organ quality and may lower inflammation-related risks, which could help prevent cancer recurrence.
    This study is an international, multicentre, randomised controlled trial (RCT) comparing the HOPE/DHOPE technique with the standard cold storage method used before transplantation. Participants will be randomly assigned to either the HOPE/DHOPE group or the control group.
    A total of 220 liver transplant recipients with HCC will take part in the study. The primary goal is to assess whether HOPE/DHOPE improves recurrence-free survival after transplantation. Secondary objectives include measuring tumour-related markers in the blood, assessing liver function, and monitoring postoperative complications.
    Participants will have regular follow-up visits for two years, including blood tests, CT scans. The study follows strict ethical guidelines and data protection regulations, ensuring patient safety and confidentiality.
    The results of this study could improve liver transplant outcomes and provide a new approach to reducing cancer recurrence, ultimately benefiting future patients worldwide.

  • REC name

    South Central - Berkshire B Research Ethics Committee

  • REC reference

    25/SC/0324

  • Date of REC Opinion

    21 Oct 2025

  • REC opinion

    Favourable Opinion